Loss of Rictor with aging in osteoblasts promotes age-related bone loss

Pinling Lai1,2, Qiancheng Song2,3, Cheng Yang1, Zhen Li1, Sichi Liu2, Bin Liu4, Mangmang Li2, Hongwen Deng1, Daozhang Cai1, Dadi Jin1, Anling Liu*3 and Xiaochun Bai*1,2

Osteoblast dysfunction is a major cause of age-related bone loss, but the mechanisms underlying changes in osteoblast function with aging are poorly understood. This study demonstrates that osteoblasts in aged mice exhibit markedly impaired adhesion to the bone formation surface and reduced mineralization in vivo and in vitro. Rictor, a specific component of the mechanistic target of rapamycin complex 2 (mTORC2) that controls cytoskeletal organization and cell survival, is downregulated with aging in osteoblasts. Mechanistically, we found that an increased level of reactive oxygen species with aging stimulates the expression of miR-218, which directly targets Rictor and reduces osteoblast bone surface adhesion and survival, resulting in a decreased number of functional osteoblasts and accelerated bone loss in aged mice. Our findings reveal a novel functional pathway important for age-related bone loss and support for miR-218 and Rictor as potential targets for therapeutic intervention for age-related osteoporosis treatment.

*Corresponding author: A Liu or X Bai, State Key Laboratory of Organ Failure Research, Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510630, China

**Abbreviations:** BMD, bone mineral density; BMSCs, bone marrow mesenchymal stem cells; BV/TV, bone volume per tissue volume; MSC, mesenchymal stem cell; mTORC2, mechanistic target of rapamycin complex 2; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; TRAP, tartrate-resistant acid phosphatase; BS, bone surface; NAC, N-acetyl-L-cysteine; ROS, reactive oxygen species

Received 04.5.16; revised 03.7.16; accepted 05.7.16; Edited by M Agostini
Loss of Rictor with aging in osteoblasts
Pinling Lai et al

osteoblast-specific Rictor deletion exhibited accelerated age-related bone loss, and identified a novel mechanism by which the increased level of reactive oxygen species (ROS) with aging stimulates miR-218 expression, which directly targets Rictor and reduces osteoblast adhesion and survival, resulting in age-related bone loss.

Results

Osteoblast adhesion and survival are markedly reduced and Rictor expression is downregulated with aging in vitro and in vivo. Age-related bone loss phenotypes were characterized in mice. Micro-computed tomography (micro-CT) analyses of the distal femur showed a marked decrease in bone mass in aged mice (16 months old) compared with young mice (3 months old), as demonstrated by a significant decrease in the trabecular bone volume per tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and bone mass density (BMD), coupled with an increase in trabecular separation (Tb.Sp) (Supplementary Figure 1). Histological and immunohistochemical analyses of femora revealed an increased number of larger area of adipocytes, characterized by fat vacuoles in the bone marrow (Supplementary Figure 2A), and decreased numbers of osteocalcin-positive osteoblasts (Figure 1a) and TRAP-positive osteoclasts on the trabecular and endosteal bone surfaces in aged mice (Supplementary Figure 2B). The bone marrow fat accumulation and decreased osteoblast number implies that there was a switch from osteogenesis to adipogenesis in the BMSCs. Interestingly, scanning electronic microscope (SEM) analyses revealed a rough trabecular bone surface with many attached cells in young mice, but a smooth trabecular bone surface with little cell adhesion in aged mice (Figure 1b). Many empty lacunae or lacunae with crimped cells (Figure 1b), accompanied with a reduction in bone formation rate (BFR) (Figure 1c), implicating decrease of osteoblast adhesion during aged-related bone loss.

To further confirm these age-related phenotypes in vitro, calvarial osteoblasts from 3- and 16-month-old mice were cultured. Osteoblasts from old mice exhibited a significantly reduced capacity for cell adhesion (Figure 1d) and mineralization (Figure 1e), but enhanced apoptosis (Figure 1f). Taken together, these findings suggest that in addition to the switch from the osteogenic differentiation to adipogenic differentiation of BMSCs, decreased osteoblast adhesion and mineralization, and enhanced apoptosis, may have important roles in aged-related osteopenia.

Rictor/mTORC2 has been shown to control both actin cytoskeletal organization and cell survival. To explore the mechanism responsible for the reduced capacity of cell adhesion and survival as osteoblasts age, trabecular bone samples were dissected from the femora of young and aged mice, and total protein was extracted to examine Rictor expression by western blotting. Interestingly, expression of Rictor and phosphorylation of mTORC2 substrate Akt(S473) were markedly reduced in the trabecular bone of aged mice (Figure 1g). In contrast, neither the level of mTORC1 (mTOR and Raptor) in bone, nor levels of Rictor in other organs including the spleen, kidney and lung, showed any significant changes with aging (Figure 1h), implicating a bone-specific downregulation of Rictor in aged mice. The downregulation of Rictor, but not mTOR or Raptor, was further confirmed in cultured primary calvarial osteoblasts from aged mice (Figure 1i). Accordingly, dephosphorylation of Akt(S473), the downstream target of Rictor/mTORC2, occurred in osteoblasts from aged mice (Figures 1g and i). Thus, we have identified aging-induced specific downregulation of Rictor in osteoblasts, which may have a role in age-related bone loss.

Deletion of Rictor in osteoblasts impairs bone formation and stimulates age-related bone loss. To investigate the role of Rictor/mTORC2 in osteoblast and bone formation, we generated conditional knockout mice with Rictor deletion limited to the osteoblasts by crossing floxed Rictor mice with Osx-GFP-Cre mice (which express a GFP-Cre fusion protein under the direction of the Osx1 promoter). We mated Osx-GFP-Cre TG/+ with Rictorflox/flox mice and selected female mice with the genotype Osx-GFP-Cre TG/+;Rictorflox/+ (hereafter referred to as OBRictorKO) for detailed analysis. Female Osx-GFP-Cre TG/+;Rictor–/– littermates served as controls. OBRictorKO mice were born at the expected Mendelian frequency, and recombination and deletion of Rictor alleles only occurred in skeletal tissues (i.e., legs and skull) as demonstrated by allele-specific PCR (Supplementary Figure 3) and western blotting (Figure 2a). Immunohistochemical staining of distal femur sections showed a dramatic decrease in P-Akt(S473) in OBRictorKO mice (Figure 2b), indicating that mTORC2 was inactivated by Rictor disruption. Although no significant differences in body weight and length were observed between Rictor-deficient mice and littermate controls at all ages. OBRictorKO mice developed osteoporosis with increasing age (Figures 2c–g and Supplementary Figure S4). In OBRictorKO mice at 6 months of age, BV/TV fell markedly compared with wild-type littermates (P<0.001; Figure 2d and Supplementary Figure S4). Cortical bone thickness (Ct.Ch) was also significantly decreased in Rictor deletion mice (Supplementary Figure S5). Histological analysis of the tibial metaphysis in 6-month-old mice showed that osteoporosis in OBRictorKO mice was associated with a striking decrease in osteoblasts (OCN-positive cells) number per unit of bone surface (Figure 2h), whereas the osteoclast number decreased slightly (Figure 2i). In keeping with these observations, serum levels of the N-terminal propeptide of type 1 procollagen (P1NP), a bone formation marker, were reduced in 6-month-old OBRictorKO mice compared with wild-type mice (Figure 2j). The BFR of 6-month-old OBRictorKO mice was also reduced compared with littermate controls (Figure 2k). In addition, no detectable adipocyte accumulation could be observed in 6-month-old OBRictorKO mice (Figure 2l). These data demonstrate that the age-related osteoporosis in OBRictorKO mice is associated with a reduction in bone formation in the face of normal osteoclast activity, but not an accumulation of bone marrow fat.

Rictor is essential for osteoblast adhesion, mineralization and survival. In order to investigate the mechanisms underlying the reduced bone formation in OBRictorKO mice, we first explored osteoblast and adipocyte differentiation in
MSC cultures prepared from OBRictorKO and wild-type mice. Although deletion of Rictor in MSCs has been reported to induce a switch from osteoblastogenesis to adipogenesis, BMSCs from OBRictorKO mice did not exhibit increased efficiency in adipogenesis (Supplementary Figure S6). This indicates that deletion of Rictor in osteoblasts did not affect BMSC differentiation, consistent with the unchanged bone marrow fat in OBRictorKO mice. However, BMSCs from OBRictorKO mice had a significantly reduced capacity to form mineralized bone nodules when cultured in osteogenic medium, accompanied by disruption of Rictor at late differentiation stages (Figures 3a and b). Similar results were obtained in cultures of calvarial osteoblasts (Figure 3c). These results suggest that deletion of Rictor in osteoblasts does not reduce osteoblastic differentiation of BMSCs, but inhibits osteoblast bone formation.

To further explain the decreased osteoblast number in the trabecular bone surface of OBRictorKO mice, the cell adhesion capacity and survival of cultured osteoblasts from OBRictorKO and wild-type mice were examined. Osteoblasts from OBRictorKO mice had a significantly reduced capacity to attach to the culture matrix and increased cleaved PARP (Figures 3d and e). Furthermore, phosphorylation of paxillin, a downstream target of Rictor that regulates cytoskeletal organization, was impaired in Rictor-deleted osteoblasts (Figure 3f). Most importantly, SEM analyses revealed diminished cell adhesion on the trabecular bone surface (Figure 3g), replicating the phenotypes seen in the osteoblasts of aged mice. Together, these findings demonstrate that Rictor is essential for osteoblast adhesion, function and survival.

Rictor is a target of miR-218 in osteoblasts. We next investigated the mechanism underlying the downregulation of Rictor expression in osteoblasts in aged mice. q-PCR analysis showed that Rictor mRNA-level in osteoblasts from aged mice remained unchanged compared with young mice (Supplementary Figure S7), suggesting that transcriptional regulation does not contribute to the downregulation of Rictor in osteoblasts.
Several microRNAs, including miR-188, miR-218, have been reported to target Rictor in human and mice cells. Thus, we performed a bioinformatic analysis of potential miRNAs targeting Rictor in mice (Supplementary Table S2). Quantitative real-time PCR analysis of the level of 13 high score miRNAs revealed that miR-218 was strongly upregulated in osteoblasts from aged mice (expression increased 1013% in osteoblasts from aged mice compared with those from young mice) (Figure 4a). Transfection of mimics of miR-218 strikingly downregulated Rictor, whereas miR-218 antagomirs upregulated Rictor protein level (Figure 4b). Accordingly, phosphorylation of Akt(S473) and paxillin, two downstream targets that mediate Rictor-regulated cell survival and actin organization, respectively, were enhanced by miR-218 mimics or reduced by miR-218 antagomirs (Figure 4c). These results suggest that both of these predicted sites contribute equally to miR-218-mediated Rictor reduction. Together, these results suggest that miR-218 directly targets Rictor in osteoblasts.

miR-218 represses osteoblast adhesion and survival by targeting Rictor. To further define the role of miR-218 in osteoblasts, the effects of miR-218 mimics and antagomirs on cell adhesion, stress-induced apoptosis in primary
osteoblasts and osteoblast cell line MC3T3-E1 were examined. miR-218 mimics reduced cell adhesion and enhanced serum starvation-induced apoptosis, whereas miR-218 antagomirs enhanced cell adhesion, but reduced apoptosis in osteoblasts (Figures 5a and b).

We next asked whether Rictor mediates the regulation of osteoblasts via miR-218. As expected, miR-218 mimics downregulated the Rictor/mTORC2 signaling pathway and phosphorylation of Akt(S473) and paxillin, whereas miR-218 antagomirs enhanced the Rictor/mTORC2 signaling pathway (Figures 5c and d). Importantly, overexpression of Rictor rescued the reduction of Akt(S473) and paxillin phosphorylation and cell adhesion and the enhancement of apoptosis by miR-218 mimics (Figures 5e–g). Together, these findings demonstrate that miR-218 represses osteoblast adhesion and survival by targeting Rictor.
ROS stimulate miR-218 to downregulate Rictor in osteoblasts from aged mice. Estrogen deficiency has been considered the primary mechanism of osteoporosis in both women and men, but epidemiological evidence in humans and recent mechanistic studies in rodents indicate that aging and the associated increase in ROS are proximal culprits.\(^{34,35}\) To explain the age-related increase of miR-218 and reduction of Rictor in osteoblasts, we further explored the potential role of ROS in this process. As expected, ROS levels were significantly elevated in the trabecular bone and osteoblast of aged mice (Figure 6a). Strikingly, hydrogen peroxide (H\(_2\)O\(_2\)) treatment increased miR-218 level by 18 times in osteoblasts (Figure 6b; Supplementary Figure S8). Accordingly, Rictor expression, P-Akt(S473) and cell adhesion were reduced, whereas apoptosis was stimulated by H\(_2\)O\(_2\) (Figures 6c–e). Expression of mTORC1 components, mTOR and Raptor was not affected (Figure 6c), indicating a specific regulation of Rictor/mTORC2 by ROS in osteoblasts. Moreover, previous studies have shown that miR-218 located at 4p15.31 and 5q35.1 within the intron of Slit2 and Slit3.\(^{36}\) We found that silencing of either Slit2 and Slit3 decreased the expression of miR-218, suggesting the regulation of miR-218 by its host genes in osteoblasts (Supplementary Figure S9).

ROS scavenger reduces miR-218 and Rictor expression and aged-related bone loss in mice. To confirm the correlation of ROS with miR-218 and Rictor expression and aged-related bone loss in vivo, aging mice were administered with ROS scavenger NAC. Because marked bone loss began from the age of 9 months in mice and significant loss of Rictor was also observed in mice at 9 months (Figure 7a), we treated mice at 7 months with NAC to prevent age-related bone loss. We found that in NAC-treated mice (16 months), trabecular bone ROS level was reduced (Figure 7b), whereas BV/TV, trabecular number and trabecular thickness were increased as compared with the control mice (Figures 7c–g; Supplementary Figure S10). Histological and IHC analyses of femora revealed a significant increase in...
the number of osteocalcin-positive osteoblasts and a slight decrease in the number of osteoclasts in NAC-treated mice (Figures 7h and i). Importantly, in addition to the impaired bone loss, miR-218 level (Figure 7j) and decreased cleaved-PARP, whereas Rictor expression and P-Akt(S473) were enhanced in NAC-treated mice (Figure 7l). These findings suggest that ROS stimulates miR-218-mediated Rictor down-regulation in osteoblasts of aged mice.

Discussion

Our studies demonstrate that downregulation of Rictor with aging in osteoblast has an important role in the pathology of age-related bone loss. Rictor is essential for bone formation by controlling osteoblast cytoskeletal organization, promoting osteoblast adhesion to the bone surface and survival, and eventually maintaining a sufficient number of functional osteoblast cells. We propose a novel functional pathway important for age-related bone loss independent of the accumulation of adipocytes in the bone marrow: accumulation of ROS with aging stimulates transcription of miR-218, which in turn targets Rictor, impairing osteoblast adhesion to the bone surface and promoting osteoblast apoptosis. In consequence, bone formation is reduced, contributing to age-related bone loss (Figure 7m). Meanwhile, other miRNAs (miR-152, miR-142, and so on) could also target to Rictor, and increased miR-218 may have other targets important for osteoblast such as Runx2 in this process (Figure 6c), all of which might contribute to age-related bone loss.5,4,6 Impaired bone formation may result from an age-related decrease in osteoblast number and function as a consequence of a multitude of intrinsic senescence-related mechanisms.7 Because progressive accumulation of fat in the bone marrow space with increasing age has been observed in age-related osteopenia, and bone marrow adipocytes and osteoblasts are thought to originate from common BMSCs, reduction in osteoblastic bone formation is thought to originate from the switch from osteoblast to adipocyte differentiation in BMSCs during aging.4–6 Many molecules including Rictor,24–26 Id4 (12), Maf,13 cannabinoid receptor type 1 (ref. 11) and miR-188 (ref. 31) have been shown to act as this molecular switch in BMSC differentiation. However, in vivo bone formation depends not only on the number and rate of the generation of osteoblasts, but also on the functional activity of osteoblasts and the lifespan of mature osteoblastic cells. Histomorphometric studies indicate that the age-related decrease in bone mass in mice is associated with increased osteoblastic and osteocytic apoptosis. This study confirms that in cells from aged individuals, more cells were apoptotic. Interestingly, the capacity of osteoblasts from aged mice to adhere to the bone surface was reduced markedly compared with that of young mice both in vitro and in vivo, which is crucial for the bone formation process. This finding emphasizes the importance of the dysregulation of osteoblast cytoskeletal organization in the pathogenesis of aged-related bone loss. Collectively, decreased osteoblast adhesion on the bone surface and increased osteoblast apoptosis reduce the number of functional osteoblasts during aged-related bone loss.

Recent studies have established the essential role of Rictor/mTORC2 in the differentiation of BMSCs, but the results from...
in vitro and in vivo studies are controversial.24–26 Both primary mouse BMSCs deficient in Rictor generated by the Cre/loxP system or BMSCs with Rictor knockdown by siRNA displayed reduced osteogenic differentiation capacity and enhanced adipogenic differentiation potential.24,26 BMSCs from mice with Rictor disruption in the limb skeletogenic mesenchyme (including BMSC) using Prx1-cre also exhibited impaired osteoblast differentiation in vitro.25 These results demonstrate that mTORC2 regulates cell-lineage selection in favor of osteoblasts over adipocytes in vitro. However, osteoblast numbers were surprisingly not reduced, but fewer bone marrow adipocytes were observed in the Rictor-deficient mice, indicating that Rictor/mTORC2 is required for proper bone marrow adipogenesis in vivo.26 Thus, the function of Rictor in BMSC lineage selection needs to be further clarified. Notably, our in vitro and in vivo studies demonstrate that Rictor is required for cytoskeletal organization, adhesion, mineralization and survival of differentiated osteoblasts. Our evidence suggests that Rictor has different roles in BMSCs and osteoblasts. Accordingly, loss of Rictor in the limb mesenchyme leads to shorter and narrower skeletal elements in both embryos and postnatal mice. These mice also

![Figure 7](image-url)
exhibited impaired bone formation, resulting in thinner cortical bones.25 However, deletion of Rictor in osteoblasts in this study did not affect bone growth during development, but accelerated bone loss with increasing age due to deficiency in mineralization, adhesion and survival of osteoblasts, indicating the essential role of Rictor in maintaining a sufficient number of functional osteoblasts and bone formation. Importantly, our study reveals the causal relationship between loss of Rictor and age-related bone loss, suggesting that Rictor downregulation with aging has a significant role in the pathogenesis of age-related osteoporosis.

Many studies have demonstrated that miRNAs have critical roles in all stages of bone formation, suggesting the possibility that miRNAs can be novel therapeutic targets for skeletal diseases.37 In BMSCs, miRNA-188 has recently been shown to regulate the age-related switch between osteoblast and adipocyte differentiation, and upregulation of miRNA-188 contributes to aged-related bone loss. Notably, miRNA-188 targets Rictor and leads to its downregulation with aging in BMSCs.38 In osteoblasts, we did not observe a significant increase in miR-188 level in aged mice. Instead, enhanced expression of miR-218 targeted Rictor and appeared to be responsible for the loss of Rictor with aging in osteoblasts. miR-218 reduces osteoblast adhesion and enhances osteoblast apoptosis, further confirming the negative role of miR-218 in bone formation. Stage-dependent regulation of Rictor by different miRNAs during osteoblast lineage differentiation highlights the complexity of the regulation of cell differentiation by miRNAs. Both miR-188 and miR-218 are potential therapeutic targets for age-related osteopenia.

In conclusion, this study demonstrates that the down-regulation of Rictor with aging in osteoblasts is important for the pathogenesis of age-related bone loss. This pathway is a novel mechanism independent of the switch of BMSCs from osteoblasts to adipocytes and bone fat accumulation. Targeting this pathway, which mediates age-related osteoblastic dysfunction, may be useful to promote bone formation and reduce bone loss associated with aging.

Materials and Methods

Materials. All reagents were obtained from Sigma (Poole Dorset, UK) unless otherwise indicated. Antibodies details for western blot analysis and immunohistochemistry can be found in Supplementary Information.

Mice. All experiments were performed in accordance and approved by the Southern Medical University Experimental Animal Welfare and Ethics Committee. Mice in which exon 11 of Rictor was flanked with a loxP site (Rictorflx/flox) were kindly provided by Professor Mark A. Magnuson at Vanderbilt University. Oster-GFP-Cre mice (cat#006361) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). We performed genotyping using genomic DNA isolated from tail biopsies, and the primers used are shown in Supplementary Table S1. C57BL/6 mice were purchased from the Laboratory Animal Centre of Southern Medical University. Nine-month-old mice were treated with NAC (oral, 2 mg/ml, dilution with water) for 3 months. Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipofectlene ( Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Confocal analysis. Osteoblast cells from OB/RictorKO and wild-type mice grown on glass coverslips in six-well plates were fixed with 4% ice-cold paraformaldehyde in phosphate-buffered saline ( PBS) for 20 min at 4°C and permeabilized with 0.2% Triton X-100 in PBS for 5 min, then blocked with goat serum for 30 min and incubated in P-Paxillin ( #1118) (at 1:100 dilution with 1% BSA) for 1 h. They were then washed in PBS for 3 × 5 min. The cells were stained with FITC-conjugated phalloidin (at 1:500 dilution with 1% BSA) and 488-conjugated secondary antibodies (at 1:250 dilution with 1% BSA) and incubated for 1 h at room temperature. Then, they were again washed in PBS for 3 × 5 min. Photomicrographs were obtained using FLOVIEW confocal microscopy (Olympus, Tokyo, Japan).

Cell adhesion assay. Primary osteoblast and MC3T3-E1 cells were trypsinized and resuspended at a concentration of 5 × 104 cells. Cells were allowed to adhere on PLAGA thin films at 37 °C for 1 h. The non-adherent cells were removed by washing with PBS three times and fixed in 70% ethanol for 15 min. The crystal violet stain solution was incubated with the adherent cells for 15 min at room temperature. The stained cells were then counted in a hemocytometer under a light microscope.

ELISA and ROS assays. Serum PIPN was measured using a mouse competitive enzyme immunoassay kit (Eliabionce, Shanghai, China), and the concentration of ROS in bone was measured according to the manufacturer’s instructions.

Preparation of decalcified sections, histochemistry and immunohistochemistry (IHC) and histomorphometric analyses. Femur tissues dissected from the mice were fixed using 4% paraformaldehyde in PBS at 4°C for 24 h and then decalcified in 15% EDTA (pH 7.4) at 4°C for 14 days. The tissues were embedded in paraffin for optimal cutting temperature compound (Sakura Finetek, Tokyo, Japan), and 2-5 μm sagittal-oriented sections were prepared for histological analyses. H&E staining was routinely performed. Tartrate-resistant acid phosphatase (TRAP) staining was performed using a standard protocol (Sigma-Aldrich). For IHC, we incubated primary antibodies which recognized mouse osteocalcin overnight at 4°C. All sections were observed and photographed on Olympus BX51 microscope (Tokyo, Japan). Immunohistochemical staining was evaluated by cell number counting. Osteoblasts on bone surface were discriminated by morphology and calculated by two independent observers blinded to the groups. At least three mice per group were examined.

Real-time PCR. Total RNA was extracted from MC3T3-E1 cells using Trizol reagent (Life Technologies, Waltham, MA, USA). TaqMan probes were used for the detection of miRNA (Applied Biosystems, Life Technologies, Waltham, MA, USA) as described by the manufacturer, by using the small nuclear RNA U6 as an endogenous control. For miRNA-level analysis, cDNA was generated by using reverse transcription of the relevant miRNA. The primers used are shown in Supplementary Table S1. All sequences were confirmed by Sanger sequencing.

Luciferase assays. HEK293 cells were transfected with the indicated pmirRNA-2 luciferase construct. All cells were also transfected with miRNA mimics or negative control. Lysates were collected 36 h after transfection and luciferase activities were measured by using the dual-luciferase reporter assay system (Promega).
miRNA detection. Total RNA, inclusive of the small RNA fraction, was extracted from cultured cells with a Tissue Total RNA Extraction Kit (GenePharma). Reverse transcription reactions were carried out using Moloney murine leukemia virus reverse transcriptase (M-MLV RT) (Invitrogen). Real-time PCR was performed on an Applied BiosystemStepOnePlus, using SYBR Green I Real-Time PCR kits (GenePharma, Suzhou, China) for miRNA. The relative expression levels of miRNAs in each sample were calculated and quantified using the 2^{-\Delta\Delta Ct} method after normalization for expression of the positive control.

Scanning electron microscopy (SEM). The surface of the methylmethacrylate (MMA) embedded femurs were polished and acid-etched with 37% phosphoric acid for 2 min. After washing for 5 min with 5% sodium hypochlorite they were coated with gold and palladium before examining with SEM (S-3700 N, Hitachi, Tokyo, Japan).

Calcein staining. Three- and nine-month-old mice were given calcein via intraperitoneal injection, 10 and 3 days before killing. Both femur were fixed in 100% ethanol, embedded in polymethyl methacrylate and sectioned using microtome (Leica SM2500S; knife: Leica VM4000, Nussloch, Germany). A total of 10 μm thick longitudinal section from each femur was analyzed using Olympus microscope. The fluorochrome labels were used to assess the bone MARs. We calculated MAR by measuring the mean distance of fluorescent labels, and dividing the distance by the time point at which the labels were administered. MAR/Ob: average thickness of mineral apposition by an osteoblast per day in 1 mm bone surface.

micro-CT analysis. Quantitative analysis was performed in mice femora at 12-μm resolution on a micro-CT Scanner (Scanco Medical, Basserdorf, Switzerland). Briefly, scanning was performed at the lower growth plate in the femora and extended proximally for 300 slices. We started morphometric analysis with the first slice in which the femoral condyles were fully merged and extended for 100 slices proximally. The 3D structure and morphometry were constructed and analyzed for BV/TV (%), BMD (mg HA/mm³), Tb.N (mm⁻¹), Tb.Th. (mm) and Tb.Sp. (mm). We also performed micro-CT imaging in the mid-diaphysis of the femur and performed mid-shaft evaluation of 100 slices to quantify the cortical thickness, bone mineral density and outerliner perimeter of the mid-shaft.

Trabecular bone ROS assay. Trabecular were isolated from femur and ground with liquid nitrogen. The homogenate in PBS was centrifuged to remove debris and the supernatants were incubated in 10 μM dichlorodihydro-fluorescein diacetate (DCFH-DA; Molecular Probes, GenePharma, Suzhou, China) for 10 min at room temperature. DCFH-DA oxidation into 2′,7′-dichlorofluorescein was measured using a spectrophotometer (Bio-TEK, Vermont, USA, excitation 485 nm and emission 525 nm). Date were expressed as value of optical density (OD).

Western blot. Cells and tissues were lysated by 2% sodium dodecyl sulfate with 10% glycerol, 10 mM Tris – HCl (pH 6.8), 10 mM dithiothreitol and 1 mM phenylmethysulfonfluoride. The lysates were centrifuged and the supernatants were separated by SDS-PAGE and blotted onto a nitrocellulose (NC) membrane (Bio-Rad Laboratories, Shanghai, China). The membrane was then analyzed using specific antibodies and visualized by enhanced chemiluminescence (ECL Kit, Amersham Biosciences, GE Healthcare, Buckinghamshire, UK).

Preparation of undecalcified histology sections. To label the mineralization fronts, 6-month-old mice were subcutaneously injected with calcin (Sigma, 15 mg/kg body weight) in 2 M urea, 10% glycerol, 10 mM Tris–HCl (pH 6.8), 10 mM dithiothreitol and 1 M phenylmethylsulfonyl fluoride. The lysates were centrifuged and the supernatants were separated by SDS–PAGE and blotted onto a nitrocellulose (NC) membrane. The membrane was then analyzed using specific antibodies and visualized by enhanced chemiluminescence (ECL Kit, Amersham Biosciences, GE Healthcare, Buckinghamshire, UK).

Statistics. All results are expressed as mean ± S.E.M. T-tests were used to calculate P-values. Statistical significance was defined as P < 0.05.

Conflict of Interest
The authors declare no conflict of interest.

Author contributions
Study conception and design: LP and BX-C. Study conduct and data acquisition: LP, SQ, YC, LZ. Analysis and interpretation of data: LP, SQ, YC, LZ, LS, LB, LM and DH. Drafting manuscript: JD, CD, LA, LP and BX-C. BX-C supervised the project and BX-C takes responsibility for the integrity of the data analysis.

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276–1287.
2. Raaij LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318–3325.
3. Canalis E, Giustina A, Bleizaff JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905–916.
4. Khosla S. Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci 2013; 68: 1226–1235.
5. Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric disease. J Am Geriatr Soc 2006; 55: 930–941.
6. Cheung CL, Xiao SM, Kung AW. Genetic epidemiology of age-related osteoporosis and its clinical applications. Nat Rev Rheumatol 2010; 6: 507–517.
7. Kassem M, Marie PJ. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 2011; 10: 191–197.
8. Liu Y, Cao X, Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J Clin Invest 2014; 124: 466–472.
9. Duyu P, Schirke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science (New York, NY) 2000; 289: 1501–1504.
10. Stevens JR, Miranda-Carboni GA, Singer MA, Bragger SM, Lyons KM, Lane TF. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 2010; 25: 2138–2147.
11. Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009; 10: 139–147.
12. Tokuzawa Y, Yagi K, Yamashita N, Nakachi Y, Nikaido I, Bono H et al. I4D, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiation. PLoS Genet 2010; 6: 7.
13. Nishikawa K, Nakashima T, Takeida S, Isogai M, Hamada M, Kimura A et al. Maf promotes osteoblast differentiation in vivo by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest 2010; 120: 3455–3465.
14. Marie PJ. Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies. Cell Mol Life Sci 2015; 72: 1347–1361.
15. Lorn F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012; 13: 27–38.
16. Cowan CM, Quarto N, Warren SM, Salim A, Longaker MT. Age-related changes in the mechanically induced cytoskeletal reorganization and lineage selection in marrow-derived mesenchymal stem cells. J Bone Miner Res 2015; 307: 1365–1377.
17. Prowse PDH, Elliott CG, Hutter J, Hamilton DW. Inhibition of Rac and ROCK signalling suggests a key factor in mTOR regulation. Cell Cycle 2010; 9: 2139–2146.
18. Bai X, Jiang Y. Key factors in mTOR regulation. Aging Cell 2010; 9: 1359–1365.
19. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signaling crosstalk. Nat Rev Mol Cell Biol 2014; 15: 156–162.
20. Albert V, Hall MN. mTOR signaling in cellular and organismal energetics. Curr Opin Cell Biol 2015; 33: 55–66.
21. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTORC complex. Science 2005; 307: 1096–1101.
22. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011; 10: 2305–2316.
23. Hagan GN, Lin Y, Magnuson MA, Avnur J, Czech MP. A Rictor-Myc/1c complex participates in dynamic cortical actin events in 3T3-L1 adipocytes. Mol Cell Biol 2006; 26: 4215–4226.
24. Ser B, Xie Z, Case N, Thompson WR, Uzer G, Stynen M et al. mTORC2 regulates mechanically induced cytoskeletal reorganization and lineage selection in marrow-derived mesenchymal stem cells. J Bone Miner Res 2014; 29: 78–89.
25. Chen J, Holguin N, Shi Y, Silva MJ, Long F. mTORC2 signaling promotes skeletal growth and bone formation in mice. J Bone Miner Res 2015; 30: 369–378.
26. Martin SK, Fitter S, Dutta AK, Matthews MP, Wakley CR, Hall MN et al. Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells 2015; 33: 1359–1365.
27. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton. Mol Biol Cell 2013; 24: 3369–3380.

Acknowledgements. This work was supported by grants from the State Key Development Program for Basic Research of China (2013CB945203 and 2015CB55360) and the National Natural Sciences Foundation of China (81330070, 31529002, 31271271 and U1301222).
29. Venkatasaran S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem 2013; 288: 1918–1928.
30. Uesugi A, Kozaki K-I, Tsuruta T, Furuta M, Morta K, Imoto I et al. The tumor suppressive microRNA miR-218 targets the mTOR component rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011; 71: 5765–5776.
31. Li C-J, Cheng P, Liang M-K, Chen YS, Lu Q, Wang JY et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest 2015; 125: 1509–1522.
32. Marcialis A, Blevins R, Graumann J, Feytout A, Dharmalingam G, Carroll T et al. microRNA-mediated regulation of mTOR complex components facilitates discrimination between activation and anergy in CD4 T cells. J Exp Med 2014; 211: 2281–2295.
33. Oneyama C, Kito Y, Asai R, Ikeda J, Yoshida T, Okuzaki D et al. MiR-424/503-mediated rictor upregulation promotes tumor progression. PLoS One 2013; 8: e60300.
34. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31: 266–300.
35. Zhang Y-B, Zhong Z-M, Hou G, Jiang H, Chen J-T. Involvement of oxidative stress in age-related bone loss. J Surg Res 2011; 169: E37–E42.
36. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J et al. miR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011; 71: 2381–2391.
37. Papaioannou G, Mirzamohammadi F, Kobayashi T. MicroRNAs involved in bone formation. Cell Mol Life Sci 2014; 71: 4747–4761.
38. Shiota C, Woo J-T, Lindner J, Shelton KD, Magnuson MA. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 2006; 11: 583–589.
39. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthr Cartil/OARS, Osteoarthritis Res Soc 2012; 20: 256–260.